These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 5820716)

  • 1. [The effect of the administration of amino acids, especially of L-dopa and alpha-methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. I. Alterations of cerebrospinal fluid in patients with parkinson's disease and normals].
    Gründig E; Gerstenbrand F; Bruck J; Gnad H; Prosenz P; Teuflmayr R
    Dtsch Z Nervenheilkd; 1969; 196(3):236-65. PubMed ID: 5820716
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of the administration of amino acids, especially of L-dopa and alpha-methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. II. Alterations of cerebrospinal fluid in patients with Parkinson's disease and chorea following the administration of alpha-methyldopa].
    Gründig E; Gerstenbrand F; Bruck J; Gnad H; Prosenz P; Simanyi M
    Dtsch Z Nervenheilkd; 1969; 196(3):256-65. PubMed ID: 5820717
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of administration of amino acids, especially of L-DOPA and -methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. 3. Alterations of cerebrospinal fluid in patients with Huntington's chorea after -methyldopa or L-DOPA].
    Simanyi M; Gerstenbrand F; Gründig E; Schedl R; Weiss H
    Z Neurol; 1973 Mar; 204(1):67-80. PubMed ID: 4121504
    [No Abstract]   [Full Text] [Related]  

  • 4. [On changes in the composition of cerebrospinal fluid in the choreatic syndrome].
    Bruck J; Gerstenbrand F; Gnad H; Gründig E; Prosenz P
    J Neurol Sci; 1967; 5(2):257-65. PubMed ID: 4228547
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; Vargas C; Gómez P; Navarro JA; Benito-León J; Ortí-Pareja M; Gasalla T; Cisneros E; Arenas J
    J Neurol Sci; 1996 Sep; 141(1-2):39-44. PubMed ID: 8880690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.
    Hare TA; Beasley BL; Chambers RA; Boehme DH; Vogel WH
    Clin Chim Acta; 1973 May; 45(3):273-80. PubMed ID: 4708057
    [No Abstract]   [Full Text] [Related]  

  • 7. 3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.
    Muenter MD; Dinapoli RP; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1973 Mar; 48(3):173-83. PubMed ID: 4570387
    [No Abstract]   [Full Text] [Related]  

  • 8. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical effects of L-dopa in Parkinson's disease].
    Fasano VA
    Sist Nerv; 1970; 22(2):119-23. PubMed ID: 5504550
    [No Abstract]   [Full Text] [Related]  

  • 10. Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease.
    Tohgi H; Abe T; Takahashi S; Nozaki Y; Kikuchi T
    Neurosci Lett; 1991 Jun; 127(2):212-4. PubMed ID: 1908962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biochemical aspects of the effect of L-dopa in patients with Parkinson's disease].
    Gründig E; Gerstenbrand F; Oberhummer J; Simanyi M; Schedl R; Weiss J
    Z Neurol; 1972; 203(1):73-90. PubMed ID: 4118094
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
    Sharpless NS; Ericsson AD; McCann DS
    Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098
    [No Abstract]   [Full Text] [Related]  

  • 14. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD; Lee JE; McDowell F
    Trans Am Neurol Assoc; 1971; 96():59-65. PubMed ID: 5159130
    [No Abstract]   [Full Text] [Related]  

  • 15. Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy.
    Lipman IJ; Papadopoulos NM
    Dis Nerv Syst; 1973 Jan; 34(1):59-62. PubMed ID: 4709194
    [No Abstract]   [Full Text] [Related]  

  • 16. [L-dopa and Parkinson's disease].
    Barbeau A
    Union Med Can; 1970 Dec; 99(12):2195-7. PubMed ID: 5488646
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopa in Parkinson's disease.
    Crawford JP
    Lancet; 1969 May; 1(7602):984. PubMed ID: 4180829
    [No Abstract]   [Full Text] [Related]  

  • 18. Serial determinations of homovanillinic acid in the cerebrospinal fluid of Parkinson patients treated with L-dopa.
    Bertler A; Jeppsson PG; Nordgren L; Rosengren E
    Acta Neurol Scand; 1971; 47(4):393-402. PubMed ID: 4941731
    [No Abstract]   [Full Text] [Related]  

  • 19. Preliminary observations on L-dopa in the treatment of Parkinson's disease.
    Jelsma F; Roth R; Ross P; Davis J
    J Ky Med Assoc; 1971 Apr; 69(4):265-9. PubMed ID: 5577419
    [No Abstract]   [Full Text] [Related]  

  • 20. Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease.
    Jansen Steur E; Vermes I; de Vos RA
    Lancet; 1998 Apr; 351(9109):1105-6. PubMed ID: 9660591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.